Abstract 297P
Background
Given a lack of standard of care treatment for patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), the objectives were to assess treatment utilization and overall survival (OS) outcomes for R/M NPC in the real-world setting.
Methods
A retrospective chart review was conducted in South Korea (SK) and Taiwan (TW) to identify patients who initiated first-line systemic therapy for R/M NPC between January 1, 2012 and June 30, 2013. Patients were followed through December 31, 2015. Stratification of study outcomes was performed per location of metastases for patients with distant metastatic disease vs. metastatic disease in distant lymph nodes only.
Results
Among 154 R/M NPC patients enrolled across 12 sites, median age was 52 years (interquartile range 45-59), 78% were male, and 87% had ECOG 0-1. In TW (N = 104), all patients had distant metastatic disease either as newly diagnosed metastatic (stage IVc) disease (32%) or disease recurrence with distant metastases (68%). In SK (N = 50), 42% of patients had distant metastatic disease, and 58% presented with distant lymph nodes only. Among patients with distant metastatic disease, patients mainly received systemic therapy only as first-line treatment in both TW (72%) and SK (67%), among which platinum + 5-FU was most common (34%). Remaining patients with distant metastatic disease received systemic therapy + radiation (28% TW; 33% SK). In contrast, patients with distant lymph nodes only in SK primarily received systemic therapy + radiation (83%). Median OS for patients with distant metastatic disease who received systemic therapy only was 23 months (95% confidence interval [CI] 18-32), compared with 32 months (95% CI: 22-Not Determined) for patients who received systemic therapy + radiation. Median OS was not reached for patients with distant lymph nodes only who received systemic therapy + radiation.
Conclusions
Differences in the location of metastases for patients with R/M NPC led to variation in treatment approaches across TW and SK. Prognosis in patients with distant metastatic disease remains poor with limited therapeutic options, underscoring the need for newer, more efficacious treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Merck and Co., Inc.
Funding
Merck and Co., Inc.
Disclosure
M-J. Ahn: Honoraria (self): Merck Sharpe and Dohme; Honoraria (self): Astra-Zeneca; Honoraria (self): Bristol Myers Squibb; Honoraria (self): Merck ; Honoraria (self): Roche; Honoraria (self): Alphas Pharmaceutical. D.R. Chirovsky: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck and Co. Inc. H. Kuyas: Research grant / Funding (institution), Full / Part-time employment: Kantar Health Division. V. Auclair: Research grant / Funding (institution), Full / Part-time employment: Kantar Health Division. S. Abounit: Research grant / Funding (institution), Full / Part-time employment: Kantar Health Division. S. Joo: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck and Co, Inc. R. Shah: Full / Part-time employment: Merck and Co, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract